Risk Factors for Arthralgias or Myalgias Associated With Quinupristin-Dalfopristin Therapy

Peggy L. Carver, Pharm.D., Emily Whang, Pharm.D., Heather L. VandenBussche, Pharm.D., Carol A. Kauffman, M.D., Preeti N. Malani, M.D.


Pharmacotherapy. 2003;23(2) 

In This Article


Of 50 evaluable patients receiving quinupristin-dalfopristin, 25 experienced pain that may have been associated with this antimicrobial agent. Multivariate and univariate analysis demonstrated a strong association between pain and quinupristin-dalfopristin therapy in patients with chronic liver disease, receipt of a liver transplant, elevated bilirubin level at baseline, and receipt of either cyclosporine or mycophenolate. The mechanism of development of arthralgias or myalgias associated with quinupristin-dalfopristin remains unknown, but these adverse effects are more likely to occur in patients with chronic liver disease and those who have undergone liver transplantation or are receiving cyclosporine or mycophenolate.

Presented at the annual meeting of the American College of Clinical Pharmacy, Tampa, Florida, October 21-24, 2001.